HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort-Reference-Cited by-同舟云学术

HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort

Published:2014-01-10 Issue:1 Volume:3 Page:134-142
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Rouanet Philippe¹,Roger Pascal²,Rousseau Emilie¹,Thibault Severine³,Romieu Gilles¹,Mathieu Andre⁴,Cretin Jacques⁴,Barneon Gilbert⁴,Granier Mireille⁴,Maran-Gonzalez Aurelie⁵,Daures Jean P.³,Boissiere Florence¹,Bibeau Frederic¹

Affiliation:

1. Montpellier Cancer Institute/Val d'Aurelle; Montpellier France

2. Department of pathology; CHU Nimes; Nimes France

3. Biostatistics, epidemiology and clinical research unit; IURC; Montpellier France

4. Onco LR; Montpellier France

5. Department of pathology; CHU Montpellier; Montpellier France

Funder

ROCHE

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.167/fullpdf

Reference36 articles.

1. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up;Rosen;J. Clin. Oncol.,1993

2. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study;Joensuu;Clin. Cancer Res.,2003

3. Management of small HER2 overexpressing tumours;Templeton;Breast Cancer Res. Treat.,2012

4. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?;Kelly;Ann. Oncol.,2011

5. Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer;Araki;Breast Cancer,2012

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus-Faced Manner;Current Oncology;2024-08-24

2. DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care;Cancers;2024-04-19

3. Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2;Monoclonal Antibodies in Immunodiagnosis and Immunotherapy;2023-04-01

4. Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis;Medicine;2022-08-05

5. Relationship between the changes of positivity rate of HER2 expression and the diameter of invasive lesions in early breast cancer and its clinical significance;Pathology - Research and Practice;2022-05